Open AccessRetrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers
Author(s) -
Poorni Manohar,
Lauren J. Beesley,
Jeremy M. G. Taylor,
Elizabeth Hesseltine,
Megan R. Haymart,
Nazanene H. Esfandiari,
David A. Hanauer,
Francis P. Worden
Publication year - 2015
Publication title -
journal of thyroid disorders and therapy
Language(s) - English
Resource type - Journals
ISSN - 2167-7948
DOI - 10.4172/2167-7948.1000188
Subject(s) - sirolimus , hazard ratio , medicine , cyclophosphamide , population , urology , oncology , everolimus , gastroenterology , chemotherapy , confidence interval , environmental health
We hypothesize that the combination of an mTOR inhibitor, sirolimus, with a well-known cytotoxic agent, cyclophosphamide, provides a well-tolerated and promising alternative treatment for advanced, differentiated thyroid cancers (DTC).